Spotlight

reports.jpg

In a recent issue of the RPM Report, Sandoz and Novartis leaders explain why changing the current naming convention for biologics could have unintended consequences for public health in the United States

Follow us

f_logo.jpg logo_youtube.jpg logo_twitter.jpg linkedin_internet.jpg

Healthcare Professionals

Portlet_HCPs

Biosimilar medicines offer physicians more choices at affordable prices thereby increasing patient access without increasing overall spending.

Payers

Portlet_Payers.jpg

Bending the curve of rising healthcare costs without compromising access to quality medical care for its citizens remains one of the most daunting challenges that governments are faced with.

Slideshow Background Images